{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.0","upperLimit":"41.1","value":"26.5"},{"groupId":"OG001","lowerLimit":"16.1","upperLimit":"45.5","value":"34.1"},{"groupId":"OG002","lowerLimit":"44.2","upperLimit":"65.4","value":"54.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-overexpressing(immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG000","title":"Cohort 1: HER2 Overexpressing"},{"description":"Participants with HER2-overexpressing (immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG001","title":"Cohort 1a: HER2 Overexpressing"},{"description":"Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG002","title":"Cohort 2: HER2 Mutated"}],"paramType":"NUMBER","populationDescription":"Objective response rate was assessed in the Full Analysis Set at data cut-off date of 03 December 2021.","reportingStatus":"POSTED","timeFrame":"From screening, up to 36 months (data cut-off)","title":"Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}